Anaplastic lymphoma kinase (ALK) and ROS1 kinase are two new driver genes implicated in ALK- and ROS1-rearranged NSCLC. Inhibition of ALK and ROS1 by crizotinib has been reported to be highly effective and well tolerated in these patients.

2022年9月3日 · Anaplastic lymphoma kinase (ALK) and ROS oncogene 1 (ROS1) gene fusions are well-established key players in non-small cell lung cancer (NSCLC).

2013年12月24日 · ALK gene rearrangement is more commonly diagnosed in lung adenocarcinoma samples than squamous or small cell tissues. ALK gene rearrangement rarely associates EGFR, HER2, or KRAS mutation, indicating that mutations in the ALK gene are found to be the subclassification of another disease.

Anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) rearrangements represent two most frequent fusion targets in lung adenocarcinoma. Our study was intended to explore the clinicopathological characteristics, coexistence and treatment of ...

2013年3月1日 · The discovery of new selective and potent inhibitors of ALK and ROS1 kinase raises the importance of using these drugs as a new method for treatment of ALK- and ROS1-derived lung cancer.

Anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) are related receptor tyrosine kinases (RTKs). Research studies have identified ALK and ROS as mutant C-terminal fusion proteins that are expressed in a wide range of cancers (1-10).

5 天之前 · Notably, ALK and ROS1 share approximately 49 % amino acid similarity in their kinase structural domains and exhibit 77 % identity in the ATP-binding region [38]. Furthermore, several ALK inhibitors, such as crizotinib and lorlatinib, have demonstrated the ability to inhibit ROS1, indicating a potential for cross-activation between ALK and ROS1.

Anaplastic lymphoma kinase (ALK) and ROS oncogene 1 (ROS1) gene fusions are well-established key players in non-small cell lung cancer (NSCLC). Although their frequency is relatively low, their detection is important for patient care and guides therapeutic decisions.